Cancer Research and Treatment

Original Articles

The Prognostic Values of Preoperative Tumor Volume and Tumor Diameter in T1N0 Papillary Thyroid Cancer: Seung Taek Lim, Ye Won Jeon, Young Jin Suh; Cancer Res Treat. 2017;49(4):890-897. Published online December 13, 2016; DOI: https://doi.org/10.4143/crt.2016.325

Purpose
The current TNM staging system for papillary thyroid cancer (PTC), which is based on tumor diameter, may not precisely reflect the true tumor burden. Therefore, we investigated whether preoperative tumor volume might more accurately reflect tumor burden and predict prognosis in patients with T1N0 PTC than preoperative tumor diameter.
Materials and Methods
We retrospectively reviewed data from 1,659 patients with T1N0 PTC, and after exclusion, a total of 1,081 patients were ultimately included. Tumor volume (V) was calculated for all patients using preoperative ultrasonography, and patientswere grouped according to tumor diameter (T1a vs. T1b) and tumor volume (V1a vs. V1b). The recurrence-free survival (RFS) rates were then compared for these groups.
Results
The mean follow-up time was 66.12±28.75 months, and 97.2% of the cohort experienced RFS. The optimal volume cut-off was defined as 0.545 cm³. There were no differences in RFS rates between T1a/T1b groups (all ages) and V1a/V1b groups (< 45 years of age). However, ≥ 45-year-old patients in the V1b group had a significantly poorer RFS rate than those in the V1a group. These results were confirmed by multivariate analysis.
Conclusion
Our results indicate that preoperative tumor volume may be more useful for predicting prognosis than tumor diameter in ≥ 45-year-old patients with T1N0 PTC.

Citations

Citations to this article as recorded by

Tumour volume is a predictor of lymphovascular invasion in differentiated small thyroid cancer
Krishna Vikneson, Tariq Haniff, May Thwin, Ahmad Aniss, Alex Papachristos, Mark Sywak, Anthony Glover
Endocrine Oncology.2022; 2(1): 42. CrossRef
Prognostic impact of dimensional factors in pT1 gastric cancer
Chikara Kunisaki, Masazumi Takahashi, Sho Sato, Nobuhiro Tsuchiya, Jun Watanabe, Tsutomu Sato, Kazuhisa Takeda, Yusaku Tanaka, Kohei Kasahara, Takashi Kosaka, Hirotoshi Akiyama, Itaru Endo
Surgical Oncology.2021; 38: 101584. CrossRef
Total thyroidectomy with and without prophylactic central compartment neck dissection in early papillary thyroid cancer: A comparative study
Hisham Omran, Ehab Mohammed Ali Fadl, Ahmed Abd El Aal Sultan
International Journal of Surgery Open.2021; 37: 100411. CrossRef
MicroRNA‑30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7
Haiyan Guo, Linyun Zhang
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Periostin silencing suppresses the aggressive phenotype of thyroid carcinoma cells by suppressing the Akt/thyroid stimulating hormone receptor axis
Min Wang, Chunyi Gui, Shenglong Qiu, Jingdong Tang, Zhihai Peng
Cytotechnology.2018; 70(1): 275. CrossRef
Comparison of incidental versus palpable thyroid nodules presenting for fine‐needle aspiration biopsy
Ayaka J. Iwata, Arti Bhan, Sharon Lahiri, Amy M. Williams, Andrew R. Taylor, Steven S. Chang, Michael C. Singer
Head & Neck.2018; 40(7): 1508. CrossRef
Prognostic influence of 3-dimensional tumor volume on breast cancer compared to conventional 1-dimensional tumor size
Ki-Tae Hwang, Wonshik Han, Sang Mok Lee, Jaewoo Choi, Jongjin Kim, Jiyoung Rhu, Young A Kim, Dong-Young Noh
Annals of Surgical Treatment and Research.2018; 95(4): 183. CrossRef
Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion
Jeung Hui Pyo, Sun-Ju Byeon, Hyuk Lee, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Kyoung-Mee Kim, Hyeon Seon Ahn, Kyunga Kim, Yoon-Ho Choi, Jae J. Kim
Oncotarget.2017; 8(69): 113758. CrossRef

9,528 View
243 Download
9 Web of Science
8 Crossref

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis: Ha-young Lee, Sang Joon Shin, Hyo Song Kim, Soo Jung Hong, Jung Woo Han, Seung Taek Lim, Jae Kyung Roh, Sun Young Rha; Cancer Res Treat. 2012;44(1):43-49. Published online March 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.1.43

Abstract PDF PubReader ePub

PURPOSE
The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD).
MATERIALS AND METHODS
A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m2) and docetaxel (35 mg/m2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients.
RESULTS
The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated.
CONCLUSION
Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.

Citations

Citations to this article as recorded by

Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
Tae Hun Kim, Ki Hyuk Sung, So Hak Chung
Journal of the Korean Orthopaedic Association.2024; 59(1): 22. CrossRef
当科における再発・進行骨軟部肉腫に対するゲムシタビン＋ドセタキセル療法の使用経験
悠太久保田, 正典河野, 達也岩﨑, 一朗糸永, 信広加来, 弘津村, 和宏田仲
Orthopedics & Traumatology.2024; 73(2): 292. CrossRef
Primary pleomorphic leiomyosarcoma of descending mesocolon
Suhaildeen Kajamohideen, Balasubramanian Venkitaraman, Sathyanarayanan M Shivkumaran, Prithviraj Premkumar
Formosan Journal of Surgery.2021; 54(5): 196. CrossRef
Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review
Maggie Zhou, Christopher Javadi, Greg W. Charville, Nam Q. Bui, E John Harris, George A. Poultsides, Jeffrey A. Norton, Brendan Visser, Byrne Lee, Monica M. Dua, Kristen N. Ganjoo
Surgical Oncology.2021; 39: 101670. CrossRef
Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab
Katherine Cotangco, Mary Meram, M. Patrick Lowe
Journal of the National Comprehensive Cancer Network.2020; 18(8): 1012. CrossRef
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Kotaro Nishida, Ryosuke Kuroda, Toshihiro Akisue
BMC Cancer.2019;[Epub] CrossRef
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim
Cancer Research and Treatment.2018; 50(1): 175. CrossRef
Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model
J. P. Frazier, E. Beirne, S. H. Ditzler, I. Tretyak, J. R. Casalini, D. J. Thirstrup, S. Knoblaugh, J. G. Ward, C. D. Tripp, R. A. Klinghoffer
Veterinary and Comparative Oncology.2017; 15(3): 754. CrossRef
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
Kazuhiro Tanaka, Susumu Joyama, Hirokazu Chuman, Hiroaki Hiraga, Hideo Morioka, Hideki Yoshikawa, Masami Hosaka, Mitsuru Takahashi, Tadahiko Kubo, Hiroshi Hatano, Mitsunori Kaya, Junya Toguchida, Yoshihiro Nishida, Akihito Nagano, Hiroshi Tsumura, Yukihid
World Journal of Surgical Oncology.2016;[Epub] CrossRef
A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma
Zhiguo Luo, Xiaowei Zhang, Wei Peng, Xianghua Wu, Huijie Wang, Hui Yu, Jialei Wang, Jianhua Chang, Xiaonan Hong
Medicine.2015; 94(43): e1777. CrossRef
Emerging therapies for adult soft tissue sarcoma
Stefano Radaelli, Sivia Stacchiotti, Paolo G Casali, Alessandro Gronchi
Expert Review of Anticancer Therapy.2014; 14(6): 689. CrossRef
A Randomized Phase II/III Trial of Perioperative Chemotherapy with Adriamycin Plus Ifosfamide Versus Gemcitabine Plus Docetaxel for High-grade Soft Tissue Sarcoma: Japan Clinical Oncology Group Study JCOG1306
K. Kataoka, K. Tanaka, J. Mizusawa, A. Kimura, H. Hiraga, A. Kawai, T. Matsunobu, A. Matsumine, N. Araki, Y. Oda, H. Fukuda, Y. Iwamoto
Japanese Journal of Clinical Oncology.2014; 44(8): 765. CrossRef
Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature
Christy S Harris, Dorothy Wang, Alison Carulli
Journal of Oncology Pharmacy Practice.2014; 20(1): 73. CrossRef
Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma - a Single Center Experience
Thomas Schmitt, Florentina Kosely, Patrick Wuchter, Johann-Wilhelm Schmier, Anthony D. Ho, Gerlinde Egerer
Oncology Research and Treatment.2013; 36(7-8): 415. CrossRef

12,240 View
68 Download
14 Crossref

First
Prev
Page of 1
Next
Last

Search